[
  {
    "ts": null,
    "headline": "AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate",
    "summary": "AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients. MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role in muscle contraction. In adults with ant",
    "url": "https://finnhub.io/api/news?id=3517e509b2206d2e92358226a89c67b92774ea23c8c87e3935af1edabdaef0c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753376923,
      "headline": "AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate",
      "id": 136082847,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients. MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role in muscle contraction. In adults with ant",
      "url": "https://finnhub.io/api/news?id=3517e509b2206d2e92358226a89c67b92774ea23c8c87e3935af1edabdaef0c8"
    }
  },
  {
    "ts": null,
    "headline": "Biosimilars Markets Global Forecast Report 2025-2035 | Launch of Glp-1 Biosimilars, Increasing Strategic Partnerships and Collaborations, & Growing Focus on Advanced R&D Fueling Opportunities",
    "summary": "The global biosimilars market is expected to surge to USD 72.29 billion by 2035, growing at a CAGR of 7.5% from USD 35.04 billion in 2025. This growth is driven by rising awareness of biosimilar safety, favorable insurance structures, and demand for cost-effective biologics. The monoclonal antibodies segment, used in treating multiple conditions like cancer and autoimmune diseases, is anticipated to see the highest growth, fueled by patent expirations and increased adoption. The US biosimilars m",
    "url": "https://finnhub.io/api/news?id=64def7810c0561b1d40f85e02022294b5572bb506e14a91f8430d10e510af1ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753350240,
      "headline": "Biosimilars Markets Global Forecast Report 2025-2035 | Launch of Glp-1 Biosimilars, Increasing Strategic Partnerships and Collaborations, & Growing Focus on Advanced R&D Fueling Opportunities",
      "id": 136066419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The global biosimilars market is expected to surge to USD 72.29 billion by 2035, growing at a CAGR of 7.5% from USD 35.04 billion in 2025. This growth is driven by rising awareness of biosimilar safety, favorable insurance structures, and demand for cost-effective biologics. The monoclonal antibodies segment, used in treating multiple conditions like cancer and autoimmune diseases, is anticipated to see the highest growth, fueled by patent expirations and increased adoption. The US biosimilars m",
      "url": "https://finnhub.io/api/news?id=64def7810c0561b1d40f85e02022294b5572bb506e14a91f8430d10e510af1ce"
    }
  },
  {
    "ts": null,
    "headline": "Looking Beyond Yield for the Safest Dividend Payers",
    "summary": "Wolfe Research screened companies for dividend growth and stable free-cash-flow yield. Here are six names that made the list.",
    "url": "https://finnhub.io/api/news?id=9220f04895af709c68301bdc291a43696c191f3d5482ff18833dc260d53a6d6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753342200,
      "headline": "Looking Beyond Yield for the Safest Dividend Payers",
      "id": 136066254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Wolfe Research screened companies for dividend growth and stable free-cash-flow yield. Here are six names that made the list.",
      "url": "https://finnhub.io/api/news?id=9220f04895af709c68301bdc291a43696c191f3d5482ff18833dc260d53a6d6f"
    }
  },
  {
    "ts": null,
    "headline": "2 Reasons to Like AMGN and 1 to Stay Skeptical",
    "summary": "Amgen’s 11.6% return over the past six months has outpaced the S&P 500 by 7.3%, and its stock price has climbed to $307.50 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=6862686ad37dd8a59e61ff14201b5994f197b2a797671d7082a9a3dc5137bb39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753329741,
      "headline": "2 Reasons to Like AMGN and 1 to Stay Skeptical",
      "id": 136066421,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen’s 11.6% return over the past six months has outpaced the S&P 500 by 7.3%, and its stock price has climbed to $307.50 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=6862686ad37dd8a59e61ff14201b5994f197b2a797671d7082a9a3dc5137bb39"
    }
  }
]